Your AI-Trained Oncology Knowledge Connection!
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor of Pharmacology, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, associate director for Translational Research, Disease Alligned Research Team Leader, Thoracic Oncology Program, Yale Cancer Center, discusses the next generation of agents coming down the pipeline in non–small cell lung cancer.
Roy S. Herbst, MD, PhD, professor, Yale Cancer Center, chief of medical oncology, Smilow Cancer Hospital at Yale-New Haven, discuses the impact of the FDA's approval of nivolumab's for the treatment of squamous non-small cell lung cancer.
Roy S. Herbst, MD, PhD, professor, Yale Cancer Center, chief of medical oncology, Smilow Cancer Hospital at Yale-New Haven, discusses the state of immunotherapy in lung cancer.
Roy S. Herbst, MD, PhD, professor, Yale Cancer Center, chief of medical oncology, Smilow Cancer Hospital at Yale-New Haven, discusses next generation lung cancer trials.
Roy S. Herbst, MD, PhD, a professor of medicine at the Yale Cancer Center and chief of medical oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, discusses new immunotherapy agents showing potential as treatment options for patients with lung cancer.
Roy S. Herbst, MD, PhD, a professor of medicine at the Yale Cancer Center and chief of medical oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, discusses the using immunotherapy agents to treat patients with lung cancer.
Roy S. Herbst, MD, PhD, a professor of medicine at the Yale Cancer Center and chief of medical oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, discusses the unique benefit of targeting the PD-1/PD-L1 pathway in lung cancer.
Roy S. Herbst, MD, PhD, discusses the sequencing possibilities of anti-PD-1 agents in treating patients with lung cancer.
Roy S. Herbst, MD, PhD, professor of Medicine at Yale Cancer Center and chief of Medical Oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, discusses the differences of targeting PD-1 and PD-L1 when treating patients with lung cancer.
Roy S. Herbst, MD, PhD, chief of Medical Oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, discusses immunotherapy for patients with lung cancer.
Roy S. Herbst, MD, PhD, from the Yale Cancer Center, describes the emergence of immunotherapy as a treatment in multiple types of cancer that was highlighted at the 2013 ASCO Annual Meeting.
Roy S. Herbst, MD, PhD, from the Yale Cancer Center, discusses determining the eligibility of patients with non-small cell lung cancer for molecular testing.
Dr. Roy S. Herbst, from Yale Cancer Center, Explores Molecular Testing in Lung Cancer
Dr. Roy S. Herbst from Yale Comprehensive Cancer Center on Themes From the 2011 Lung Cancer Congress
Dr. Roy S. Herbst from Yale comprehensive cancer center on the International Lung Cancer Congress
Dr. Roy Herbst from the Yale Comprehensive Cancer Center on Screening Studies at the Upcoming Lung Cancer Congress